AI-generated summary
The authors systematically reviewed nine in vitro and in vivo studies examining photobiomodulation therapy combined with cisplatin for various cancers. They report that most cell studies showed enhanced cancer cell inhibition and apoptosis compared with cisplatin alone, and the single animal model reported reduced cisplatin-induced acute renal failure. Authors describe the combination as appearing safe and effective, but evidence comes from laboratory and animal models and clinical trials are still needed.
- Studies included
- 9
- Who or what was studied
- Cancer cell lines and animal models treated with cisplatin combined with photobiomodulation therapy, across various cancers
- Limits stated in the abstract
- Evidence comes from in vitro and in vivo models, with only one animal model, and the authors state clinical trials are needed to validate the findings.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Systematic review, Reactive oxygen species, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.